In the context of the global obesity epidemic, the FDA approved several glucagon-like peptide-1 (GLP-1) receptor agonists (GPL-1RAs), such as liraglutide (Saxenda) and semaglutide (Ozempic, Wegovy) as ...

Tirzepatide, a once-weekly GIP/GLP-1 receptor agonist, is a medicine used for weight reduction in adults with obesity. A new analysis of the SURMOUNT clinical trials reveals that the medicine, ...

(RTTNews) - Eli Lilly and Co. (LLY) announced that Zepbound (tirzepatide) demonstrated a significantly greater weight reduction compared to Wegovy (semaglutide) in all comparisons conducted during the ...

A massive international study has shown that the experimental oral obesity drug orforglipron can help patients shed over 10% of their body weight, with nearly one in five losing 20% or more. Unlike ...

March 19 (Reuters) - Eli Lilly (LLY.N), opens new tab's next-generation obesity drug showed a significant reduction in blood sugar levels and weight in a late-stage trial, the company said on Thursday ...

Trial results showed the "Wegovy pill" led to average weight reduction of 16.6% after 64 weeks, Novo Nordisk said. The company's Chief Science Officer Martin Holst Lange told CNBC that oral treatment ...

Share on Pinterest Weight loss drugs may offer added heart-health benefits, such as reducing blood pressure levels. Image credit: Design by MNT; Photography by Tatiana Maksimova/Getty Images A ...

Please provide your email address to receive an email when new articles are posted on . Adults enrolled in an eating pattern designed for rapid weight loss had a body weight reduction of 14.4% at 1 ...